How exactly do oncolytic viruses help fight cancer?

Hello,

Welcome to icliniq.com.

I read your query and can understand your concern.

1. Selective targeting of cancer cells: Oncolytic viruses are genetically engineered or naturally occurring viruses modified to selectively target cancer cells while sparing normal, healthy cells. They are designed to exploit the unique characteristics of cancer cells, such as altered signaling pathways (abnormal communication networks within cells), defective antiviral responses, and overexpression of specific receptors on the cell surface.

2. Infection and replication within cancer cells: Once inside the body, oncolytic viruses specifically infect cancer cells by binding to receptors on the surface of these cells. Upon entry into the cancer cell, the virus undergoes replication (a process of creating more copies of itself) and amplification (an increase in the number of viral particles), producing multiple copies of the virus within the cancer cell.

3. Cell lysis and tumor destruction: As the oncolytic virus replicates within the cancer cell, it eventually causes it to lyse or burst open, releasing newly synthesized viral particles into the surrounding tumor microenvironment. This process not only destroys the infected cancer cell but also exposes tumor antigens (proteins from the tumor that trigger an immune response) and activates the immune system to recognize and attack other cancer cells nearby.

4. Induction of antitumor immune response: In addition to directly killing cancer cells, oncolytic viruses can also stimulate the immune system to mount an antitumor immune response. The release of viral particles and tumor antigens from lysed cancer cells triggers the recruitment of immune cells, such as T cells (a type of white blood cell involved in immune responses), natural killer (NK) cells, and dendritic cells, to the tumor site. These immune cells help to amplify and sustain the antitumor immune response, leading to the elimination of cancer cells and the development of long-lasting immunity against the tumor.

5. Enhancement of systemic antitumor immunity: Beyond the direct effects on the tumor site, oncolytic viruses can also induce systemic antitumor immunity, resulting in the regression of distant metastases (spread of cancer to other parts of the body) and the prevention of tumor recurrence. This systemic immune response may involve the activation of memory T cells and the production of antitumor antibodies that target cancer cells throughout the body.

Oncolytic viruses are designed to selectively infect and kill cancer cells while sparing normal, healthy cells.

Several mechanisms contribute to this selective targeting:

1. Altered receptor expression: Many oncolytic viruses are engineered to target cancer cells specifically by exploiting the overexpression of certain receptors or surface proteins on the cancer cell membrane. These receptors may be upregulated in cancer cells as a result of genetic mutations (changes in the DNA sequence) or alterations in signaling pathways. By targeting these receptors, oncolytic viruses can preferentially bind to and enter cancer cells while sparing normal cells that lack the specific receptor expression.

2. Defective antiviral responses: Cancer cells often exhibit defects in their antiviral defense mechanisms, making them more susceptible to viral infection compared to normal cells. For example, cancer cells may have impaired interferon signaling pathways or dysfunctional apoptotic pathways (processes that lead to programmed cell death), allowing oncolytic viruses to replicate more efficiently within cancer cells and induce cell death.

3. Differences in cellular environment: The microenvironment of cancer cells differs from that of normal cells in several ways, including altered pH, oxygen levels, and nutrient availability. Oncolytic viruses may be engineered to exploit these differences to selectively replicate and propagate within cancer cells while being less effective in normal cells. For example, some oncolytic viruses require specific cellular conditions or factors present only in cancer cells for efficient replication and spread.

4. Tumor-specific promoters: Oncolytic viruses can be engineered to contain tumor-specific promoters that drive viral gene expression selectively in cancer cells. These promoters are active only in cancer cells due to the presence of specific genetic mutations or alterations. By incorporating tumor-specific promoters into the viral genome, oncolytic viruses can limit viral replication and gene expression to cancer cells, minimizing off-target effects on normal cells.

5. Immune-mediated targeting: In addition to direct oncolysis (destruction of cancer cells by viruses), oncolytic viruses can stimulate antitumor immune responses that contribute to the selective destruction of cancer cells. The release of viral particles and tumor antigens from lysed cancer cells activates the immune system, leading to the recruitment of immune cells that recognize and eliminate cancer cells throughout the body. This immune-mediated targeting helps to amplify the therapeutic effects of oncolytic viruses while minimizing damage to normal tissues.

I hope this helps.